ArticleJAMA dermatology2018
Combined Systemic and Intratumoral Administration of Human Papillomavirus Vaccine to Treat Multiple Cutaneous Basaloid Squamous Cell Carcinomas.
Article in JAMA dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 77 citations in OpenAlex.
- The human skin virome: Ecological dynamics, aberrant profiles, and therapeutic opportunities.Cell host & microbe · 2026Review
- Non-melanoma skin cancer and HPV in persons with albinism: a call for research investment.British journal of cancer · 2025Review
- Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumors.NPJ vaccines · 2025Article
- Review
- Nanoemulsions in Skin Cancer Therapy: A Promising Frontier.Current pharmaceutical biotechnology · 2025Review
- Infectious etiologies of conjunctival tumors.Expert review of ophthalmology · 2025Article
- Review
- Diagnosis and Management of Malignant Epithelial Nail Unit Tumors.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Update on Squamous Cell Carcinoma of the Nail Unit: An Human Papillomavirus-Associated Condition.Skin appendage disorders · 2024Review
- A Comprehensive Review of Various Therapeutic Strategies for the Management of Skin Cancer.ACS omega · 2024Review
- Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases-A Comprehensive Review.Vaccines · 2024Review
- Review
- Article
- Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming.Journal for immunotherapy of cancer · 2023Article
- Therapeutic Cancer Vaccines for Nonmelanoma Skin Cancer.Current treatment options in oncology · 2023Review
- Anterior segment optical coherence tomography characteristics of conjunctival papilloma as compared to papilliform ocular surface squamous neoplasia.Eye (London, England) · 2023Article
- Resolution of a Presumed Conjunctival Papilloma After Therapeutic Treatment With the Human Papillomavirus Vaccine.JAMA ophthalmology · 2022Article
- Giant condyloma of Buschke-Lowenstein in a patient with pemphigus vegetans treated with intralesional and systemic human papillomavirus vaccine.JAAD case reports · 2022Article
- Skin cancer biology and barriers to treatment: Recent applications of polymeric micro/nanostructures.Journal of advanced research · 2022Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Squamous cell carcinoma (SCC) is the second most common form of skin cancer, and its incidence is increasing. When surgical management is not an option, finding a safe and efficacious treatment is a challenge. Mounting evidence suggests that the human papillomavirus (HPV) is involved in the pathogenesis of some SCCs. Objective: To assess whether the 9-valent HPV vaccine could be an effective treatment strategy for cutaneous SCC. Design, Setting, and Participants: A woman in her 90s with multiple, inoperable cutaneous basaloid SCCs was successfully treated at a university-based outpatient dermatology clinic with a combination of systemic and intratumoral delivery of the 9-valent HPV vaccine from March 17, 2016, through February 27, 2017, and then followed up through May 21, 2018. Main Outcomes and Measures: Reduction in tumor size and number after a combination of systemic and intratumoral administration of the HPV vaccine. Results: All tumors resolved 11 months after the first intratumoral injection of the vaccine. The patient remained free of tumors at the end of follow-up. Conclusions and Relevance: This is the first report, to our knowledge, of complete regression of a cutaneous malignant tumor after combined systemic and direct intratumoral injection of the 9-valent HPV vaccine. This report suggests that the HPV vaccine may have therapeutic utility for SCCs in patients who are poor surgical candidates, have multiple lesions, or defer surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.